David R. Gastfriend Explained

David R. Gastfriend is an American psychiatrist, internationally[1] recognized addiction treatment researcher,[2] [3] [4] the former Chief Executive Officer of the Treatment Research Institute (TRI),[5] [6] and current Chief Medical Officer of DynamiCare Health.[7] [8]

In April 2017, the Patient-Centered Outcomes Research Institute awarded a $13-million-dollar, 5-year grant to TRI to study addiction treatment with Gastfriend as principal investigator.[9] [10] [11] [12] It will be the first large-scale trial to integrate the evidence-based practices in the Personalized Addiction Treatment to Health (PATH) model—such as cognitive-behavioral relapse prevention, peer support, contingency management, and FDA-approved medications—and compare them with standard care practices typically offered to patients with opioid use disorders (OUD). With 800 OUD patients, it will be one of the largest ever randomized controlled clinical trials of addiction treatment.

Professional activities

A senior fellow of the American Society of Addiction Medicine (ASAM), Gastfriend led development of the ASAM criteria for placing patients in addiction treatment programs,[13] now standard in more than 30 US states.[14] [15] These criteria became the basis of ASAM's assessment software "Continuum",[16] which will be deployed in the TRI study.

Gastfriend was Vice President for Scientific Communications at the pharmaceutical company Alkermes[17] from 2004 to 2013. While there he co-authored a 2011 study[18] instrumental in getting FDA approval of injectable naltrexone (Vivitrol)[19] for the treatment of alcohol and opioid dependence.

In 2012 he received the John P. McGovern Award for "highly meritorious contributions to addiction and society in public policy, treatment, research or prevention" from the ASAM.[20] Gastfriend has worked as a consultant for the governments of Belgium, China, Iceland, Israel, Norway, Russia and the U.S.,[21] [22] as well as the alcoholism and opioid-addition treatment company[23] BioCorRx.[24]

External links

Notes and References

  1. News: Pennsylvania opts for a different tool to assess drug abuse Reading Eagle - NEWS. Reading Eagle. September 12, 2017. en.
  2. News: This Opioid Treatment Model That Provides All Levels Of Care Is Spawning Imitators. Stateline. Pew's. April 27, 2016. Huffington Post. September 12, 2017. en-US.
  3. News: Third of Philadelphians used prescription opioids in the last year, survey finds. Philly.com. September 12, 2017.
  4. News: Drug may give those leaving jail a better shot at recovery. Freyer. Felice. December 20, 2015. The Boston Globe. September 11, 2017.
  5. Web site: David R. Gastfriend M.D. : Executive Profile & Biography - Bloomberg. www.bloomberg.com. September 11, 2017.
  6. Web site: Treatment Research Institute names new CEO. August 14, 2014. www.bizjournals.com. September 11, 2017.
  7. News: BioCorRx Announces Beta Launch of Mobile Application for Opioid and Alcohol Substance Use Disorder. BioCorRx Inc.. September 12, 2017. Nasdaq Marketwired. September 12, 2017.
  8. News: BioCorRx Reports 12% Increase in Revenue and Provides Business Update for the Second Quarter of 2017. August 15, 2017. UPTICK Newswire. September 11, 2017. en-US. September 12, 2017. https://web.archive.org/web/20170912192743/https://upticknewswire.com/biocorrx-reports-12-increase-revenue-provides-business-update-second-quarter-2017/. dead.
  9. News: Treatment Research Institute Approved for $13 Million Research Funding Award by the U.S. Patient-Centered Outcomes Research Institute. PRWeb. September 11, 2017.
  10. Web site: General health clinics, specialty care will go head-to-head in opioid treatment study Addiction Professional Magazine. www.addictionpro.com. en. September 11, 2017.
  11. News: ASAM's Assessment Software CONTINUUM™ to be Used in Significant Clinical Trial. May 1, 2017. Continuum ASAM Criteria Decision Engine. September 12, 2017. en-US. September 12, 2017. https://web.archive.org/web/20170912194211/http://asamcontinuum.org/asams-assessment-software-continuum-to-be-used-in-significant-clinical-trial/. dead.
  12. Web site: A Simple Large Trial of Patient-Centered Care for Opioid Use Disorders in Federally Qualified Healthcare Centers and Specialty Care Settings. www.pcori.org. March 15, 2017 . en. September 12, 2017.
  13. Web site: ASAM Patient Placement Criteria - Oversight and Revision. May 2011. September 11, 2017. September 28, 2016. https://web.archive.org/web/20160928165754/http://www.asam.org/docs/publications/asam_ppc_oversight_may_2011628052550F25.pdf?Status=Master&sfvrsn=2. dead.
  14. Web site: Current State AOD Agency Practices Regarding the Use of Patient Placement Criteria (PPC) - An Update. Kolsky. Gretchen D.. November 1, 2006. www.asam.org. The National Association of State Alcohol and Drug Abuse Directors. September 12, 2017. May 5, 2017. https://web.archive.org/web/20170505004436/http://www.asam.org/docs/publications/survey_of_state_use_of_ppc_nasadad-2006.pdf?Status=Master&sfvrsn=2. dead.
  15. News: Pennsylvania to adopt ASAM guidelines for addiction treatment • Addiction Now Substance Abuse, Drug Addiction and Recovery News Source. Gamboa. Cesar. April 3, 2017. Addiction Now Substance Abuse, Drug Addiction and Recovery News Source. September 12, 2017. en-US.
  16. Web site: ASAM Criteria evolves into electronic tool Behavioral Healthcare Magazine. www.behavioral.net. en. September 12, 2017.
  17. Web site: The Last Shot — ProPublica. June 27, 2017. ProPublica. en-us. Alec MacGillis. September 11, 2017.
  18. Krupitsky. Evgeny. Nunes. Edward V.. Ling. Walter. Illeperuma. Ari. Gastfriend. David R.. Silverman. Bernard L.. April 28, 2011. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. PDF. The Lancet. 377. 9776. 1506–13. 10.1016/s0140-6736(11)60358-9. 21529928. 16690413. June 11, 2017.
  19. Web site: A Shot in the Dark: Can Vivitrol Help Us Control Our Addictions?. May 7, 2013.
  20. Web site: ASAM Award Programs. www.asam.org. September 11, 2017.
  21. News: Faculty. Addiction eXecutives Industry Summit. September 12, 2017. en-US.
  22. Web site: Evidence-based Public Health Week: From the Streets to the ER: The Opioid Analgesic Epidemic. Center for Public Health Initiatives. www.cphi.upenn.edu/. September 12, 2017.
  23. Web site: Profile: BioCorRx Inc. Reuters. September 11, 2017.
  24. Web site: Bloomberg: Company Overview of BioCorRx Inc.. www.bloomberg.com. September 11, 2017.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "David R. Gastfriend".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.